PBE:NYE-Invesco Dynamic Biotechnology & Genome ETF (USD)

ETF | Health |

Last Closing

USD 68.86

Change

-2.34 (-3.29)%

Market Cap

N/A

Volume

4.50K

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-14 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

-2.31 (-1.57%)

USD 40.46B
FHLC Fidelity® MSCI Health Care In..

-1.17 (-1.67%)

USD 2.91B
FXH First Trust Health Care AlphaD..

-2.16 (-1.94%)

USD 1.19B
XHE SPDR® S&P Health Care Equipme..

-1.78 (-1.96%)

USD 0.22B
IDNA iShares Genomics Immunology an..

-0.66 (-2.70%)

USD 0.15B
SBIO ALPS Medical Breakthroughs ETF

-1.18 (-2.93%)

USD 0.13B
XHS SPDR® S&P Health Care Service..

-2.68 (-2.80%)

USD 0.08B
HTEC Robo Global® Healthcare Techn..

-0.79 (-2.68%)

USD 0.06B
BBP Virtus LifeSci Biotech Product..

-1.78 (-2.73%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

-0.93 (-3.17%)

USD 0.01B

ETFs Containing PBE

WBIR 0.00 % 1.25 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 4.59% 19% F 44% F
Dividend Return 0.05% 13% F 1% F
Total Return 4.64% 19% F 33% F
Trailing 12 Months  
Capital Gain 24.39% 76% C+ 67% D+
Dividend Return 0.06% 11% F 1% F
Total Return 24.44% 71% C- 62% D
Trailing 5 Years  
Capital Gain 31.76% 48% F 63% D
Dividend Return 0.14% 11% F 1% F
Total Return 31.91% 43% F 53% F
Average Annual (5 Year Horizon)  
Capital Gain 6.15% 62% D 56% F
Dividend Return 6.16% 52% F 49% F
Total Return 0.01% 11% F 1% F
Risk Return Profile  
Volatility (Standard Deviation) 21.06% 48% F 52% F
Risk Adjusted Return 29.26% 52% F 46% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.